In vitro and in vivo targeting imaging of pancreatic cancer using a Fe3O4@SiO2 nanoprobe modified with anti-mesothelin antibody
Fang Liu,1,* Wenjun Le,2,* Tianxiao Mei,2 Tiegong Wang,1 Luguang Chen,1 Yi Lei,1 Shaobin Cui,2 Bingdi Chen,2 Zheng Cui,2,3 Chengwei Shao1 1Radiology Department of Changhai Hospital, Second Military Medical University, 2Shanghai East Hospital, The Institute for Biomedical Engineering & Nano...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8bcb27d915e44c9e94d313bd8797b21c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8bcb27d915e44c9e94d313bd8797b21c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8bcb27d915e44c9e94d313bd8797b21c2021-12-02T00:45:22ZIn vitro and in vivo targeting imaging of pancreatic cancer using a Fe3O4@SiO2 nanoprobe modified with anti-mesothelin antibody1178-2013https://doaj.org/article/8bcb27d915e44c9e94d313bd8797b21c2016-05-01T00:00:00Zhttps://www.dovepress.com/in-vitro-and-in-vivo-targeting-imaging-of-pancreatic-cancer-using-anbs-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Fang Liu,1,* Wenjun Le,2,* Tianxiao Mei,2 Tiegong Wang,1 Luguang Chen,1 Yi Lei,1 Shaobin Cui,2 Bingdi Chen,2 Zheng Cui,2,3 Chengwei Shao1 1Radiology Department of Changhai Hospital, Second Military Medical University, 2Shanghai East Hospital, The Institute for Biomedical Engineering & Nano Science, Tongji University School of Medicine, Shanghai, People’s Republic of China; 3Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, USA *These authors contributed equally to this work Abstract: Pancreatic cancer is a highly malignant disease with a 5-year survival rate ,5% mainly due to lack of early diagnosis and effective therapy. In an effort to improve the early diagnostic rate of pancreatic cancer, a nanoprobe Fe3O4@SiO2 modified with anti-mesothelin antibody (A-MFS) was prepared to target cells and tumor tissues highly expressing mesothelin in vitro (human pancreatic cancer cell line SW1990) and in vivo (subcutaneously transplanted tumors) studies. The A-MFS probe was successfully prepared and was spherical and uniform with a hydrodynamic diameter between 110 and 130 nm. Cell Counting Kit-8 testing indicated that A-MFS was nontoxic in vitro and in vivo studies. The in vitro study showed that the A-MFS probe specifically targeted SW1990 cells with high mesothelin expression. The in vivo study was conducted in Siemens 3.0 T magnetic resonance imaging. The average T2-weighted signal values of the xenografts were 966.533±31.56 before injecting A-MFS and 691.133±56.84 before injecting saline solution. After injection of 0.1 mL A-MFS via nude mouse caudal vein for 2.5 hours, the average T2-weighted signal of the xenograft decreased by 342.533±42.6. The signal value decreased by -61.233±33.9 and -58.7±19.4 after injection of the saline and Fe3O4@SiO2. The decrease of tumor signal by A-MFS was much more significant than that by saline and Fe3O4@SiO2 (P<0.05). The results demonstrated the high stability and nontoxicity of A-MFS, which effectively targeted pancreatic cancer in vitro and in vivo. A-MFS is a promising agent for diagnosis of pancreatic cancer. Keywords: nanoprobe, mesothelin, Fe3O4@SiO2, pancreatic cancer, targeted imagingLiu FLe WMei TWang TChen LLei YCui SChen BCui ZShao CDove Medical PressarticlenanoprobemesothelinFe3O4@SiO2pancreatic cancertargeted imagingMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2016, Iss default, Pp 2195-2207 (2016) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
nanoprobe mesothelin Fe3O4@SiO2 pancreatic cancer targeted imaging Medicine (General) R5-920 |
| spellingShingle |
nanoprobe mesothelin Fe3O4@SiO2 pancreatic cancer targeted imaging Medicine (General) R5-920 Liu F Le W Mei T Wang T Chen L Lei Y Cui S Chen B Cui Z Shao C In vitro and in vivo targeting imaging of pancreatic cancer using a Fe3O4@SiO2 nanoprobe modified with anti-mesothelin antibody |
| description |
Fang Liu,1,* Wenjun Le,2,* Tianxiao Mei,2 Tiegong Wang,1 Luguang Chen,1 Yi Lei,1 Shaobin Cui,2 Bingdi Chen,2 Zheng Cui,2,3 Chengwei Shao1 1Radiology Department of Changhai Hospital, Second Military Medical University, 2Shanghai East Hospital, The Institute for Biomedical Engineering & Nano Science, Tongji University School of Medicine, Shanghai, People’s Republic of China; 3Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, USA *These authors contributed equally to this work Abstract: Pancreatic cancer is a highly malignant disease with a 5-year survival rate ,5% mainly due to lack of early diagnosis and effective therapy. In an effort to improve the early diagnostic rate of pancreatic cancer, a nanoprobe Fe3O4@SiO2 modified with anti-mesothelin antibody (A-MFS) was prepared to target cells and tumor tissues highly expressing mesothelin in vitro (human pancreatic cancer cell line SW1990) and in vivo (subcutaneously transplanted tumors) studies. The A-MFS probe was successfully prepared and was spherical and uniform with a hydrodynamic diameter between 110 and 130 nm. Cell Counting Kit-8 testing indicated that A-MFS was nontoxic in vitro and in vivo studies. The in vitro study showed that the A-MFS probe specifically targeted SW1990 cells with high mesothelin expression. The in vivo study was conducted in Siemens 3.0 T magnetic resonance imaging. The average T2-weighted signal values of the xenografts were 966.533±31.56 before injecting A-MFS and 691.133±56.84 before injecting saline solution. After injection of 0.1 mL A-MFS via nude mouse caudal vein for 2.5 hours, the average T2-weighted signal of the xenograft decreased by 342.533±42.6. The signal value decreased by -61.233±33.9 and -58.7±19.4 after injection of the saline and Fe3O4@SiO2. The decrease of tumor signal by A-MFS was much more significant than that by saline and Fe3O4@SiO2 (P<0.05). The results demonstrated the high stability and nontoxicity of A-MFS, which effectively targeted pancreatic cancer in vitro and in vivo. A-MFS is a promising agent for diagnosis of pancreatic cancer. Keywords: nanoprobe, mesothelin, Fe3O4@SiO2, pancreatic cancer, targeted imaging |
| format |
article |
| author |
Liu F Le W Mei T Wang T Chen L Lei Y Cui S Chen B Cui Z Shao C |
| author_facet |
Liu F Le W Mei T Wang T Chen L Lei Y Cui S Chen B Cui Z Shao C |
| author_sort |
Liu F |
| title |
In vitro and in vivo targeting imaging of pancreatic cancer using a Fe3O4@SiO2 nanoprobe modified with anti-mesothelin antibody |
| title_short |
In vitro and in vivo targeting imaging of pancreatic cancer using a Fe3O4@SiO2 nanoprobe modified with anti-mesothelin antibody |
| title_full |
In vitro and in vivo targeting imaging of pancreatic cancer using a Fe3O4@SiO2 nanoprobe modified with anti-mesothelin antibody |
| title_fullStr |
In vitro and in vivo targeting imaging of pancreatic cancer using a Fe3O4@SiO2 nanoprobe modified with anti-mesothelin antibody |
| title_full_unstemmed |
In vitro and in vivo targeting imaging of pancreatic cancer using a Fe3O4@SiO2 nanoprobe modified with anti-mesothelin antibody |
| title_sort |
in vitro and in vivo targeting imaging of pancreatic cancer using a fe3o4@sio2 nanoprobe modified with anti-mesothelin antibody |
| publisher |
Dove Medical Press |
| publishDate |
2016 |
| url |
https://doaj.org/article/8bcb27d915e44c9e94d313bd8797b21c |
| work_keys_str_mv |
AT liuf invitroandinvivotargetingimagingofpancreaticcancerusinganbspfe3o4sio2nbspnanoprobemodifiedwithantimesothelinantibody AT lew invitroandinvivotargetingimagingofpancreaticcancerusinganbspfe3o4sio2nbspnanoprobemodifiedwithantimesothelinantibody AT meit invitroandinvivotargetingimagingofpancreaticcancerusinganbspfe3o4sio2nbspnanoprobemodifiedwithantimesothelinantibody AT wangt invitroandinvivotargetingimagingofpancreaticcancerusinganbspfe3o4sio2nbspnanoprobemodifiedwithantimesothelinantibody AT chenl invitroandinvivotargetingimagingofpancreaticcancerusinganbspfe3o4sio2nbspnanoprobemodifiedwithantimesothelinantibody AT leiy invitroandinvivotargetingimagingofpancreaticcancerusinganbspfe3o4sio2nbspnanoprobemodifiedwithantimesothelinantibody AT cuis invitroandinvivotargetingimagingofpancreaticcancerusinganbspfe3o4sio2nbspnanoprobemodifiedwithantimesothelinantibody AT chenb invitroandinvivotargetingimagingofpancreaticcancerusinganbspfe3o4sio2nbspnanoprobemodifiedwithantimesothelinantibody AT cuiz invitroandinvivotargetingimagingofpancreaticcancerusinganbspfe3o4sio2nbspnanoprobemodifiedwithantimesothelinantibody AT shaoc invitroandinvivotargetingimagingofpancreaticcancerusinganbspfe3o4sio2nbspnanoprobemodifiedwithantimesothelinantibody |
| _version_ |
1718403511078617088 |